AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$MNKD

Binder Steven B. sold $128K of MNKD

Binder Steven B. sold 33,558 shares of MANNKIND CORP (MNKD) at $3.81 ($0.13M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Binder Steven B.
Published Sep 15, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 12:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MNKD
Neutral
medium confidence
Mentioned
$MNKD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNKDNeutralLow
01

Why it matters

The director's sale is modest; investors may monitor for further insider activity.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming clinical trial results or financing events not disclosed.

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-14, after market close

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

$MNKDNeutralMedium confidence
Context

Director Binder Steven B. sold 33,558 shares of MannKind Corp for $127,856 via a 10b5-1 plan.

Expected impact

Limited short-term pressure; unlikely to move price materially.

Evidence & confidence

Sale size (~$128K) is small compared to total holdings (752,309 shares) and market cap, so impact is minimal.

Market effects

Sector

No broader sector impact; MannKind operates in biotech niche.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be routine liquidity need rather than a negative signal.

Key entities

  • Company
    MannKind Corp

    Biopharmaceutical company developing inhalable insulin.

  • Individual
    Binder Steven B.

    Director of MannKind Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MNKD insider trading history →

Related articles

$MNKDMed

MannKind (MNKD) Q3 2026 Earnings Call Transcript

MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.

finance.yahoo.com
$MNKDMed

Cantor Fitzgerald raises MannKind stock price target to $10 on Tyvaso momentum

Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.

investing.com
$MNKDHigh

MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update

MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 o Furoscix ReadyFlow ™ was approved and shipments commenced mid

SEC EDGAR 8-K
$MNKDMedAI 8/10

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

MannKind (MNKD) presented clinical data at HFSA 2026 showing Furoscix ReadyFlow's comparable urine output to IV furosemide. The autoinjector delivers an 80 mg/mL dose in under 10 seconds, with 91.3% and 92.7% bioavailability in thigh and upper-arm injections, respectively. ReadyFlow received FDA approval in July 2026 for fluid overload treatment in heart failure or CKD patients.

stocktitan.net